2,4,6-三乙基吡啶 | 50286-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,4,6-三乙基吡啶
• 中文别名: 二[3-[4,5-二氢-4-[(2-羟基-5-甲基-3-硝基苯基)偶氮]-3-甲基-5-羰基-1H-吡唑-1-基]苯-1-磺基酰胺酸根(2-)]铬酸(1-)氢,混合物和2-乙基-1-己基胺(1:1)
• 英文名称: 2,4,6-triethylpyridine
• 英文别名: 2,4,6-triethyl-pyridine；2,4,6-Triaethyl-pyridin；2,4,6-Triethyl-pyridin；2,4,6-Triethylpyridin；Pyridine, 2,4,6-triethyl-
• CAS: 50286-76-5
• 化学式: C₁₁H₁₇N
• 分子量: 163.263
• InChiKey: XVMNXGCQCHNBEN-UHFFFAOYSA-N

物化性质

• 保留指数：
  1212

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  2-氯代-2-甲基丁烷 在 二硫化碳 、 ammonium hydroxide 、 三氯化铝 、 高氯酸 作用下， 生成 2,4,6-三乙基吡啶
  参考文献：
  名称：

  Balaban; Nenitzescu, Justus Liebigs Annalen der Chemie, 1959, vol. 625, p. 74,83

  摘要：

  DOI：

文献信息

• Inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction
  申请人：——

  公开号：US20030064989A1

  公开（公告）日：2003-04-03

  The invention concerns inhibitors of cell proliferation, angiogenesis, fertility, and muscle contraction, characterized by formula I 1 wherein, X, Y and Z independently represent C or N; ------ is an optional double bond; n is 0 or 1; R 1 , R 2 , and R 4 independently represent hydrogen, a chemical bond, C 1-10 alkyl; C 2-10 alkenyl; C 2-10 alkinyl; aryl; aryl-C 1-10 alkyl; C 3-10 heterocyclyl; C 5-10 heteroaryl; halo, CF 3 ; NO 2 ; NHC(O)R*, OR, said alkyl, alkenyl, alkinyl, aryl, arylalkyl, heterocyclyl, or heteroaryl being optionally substituted; R 3 , R 5 , and R 6 independently represent hydrogen, C 1-10 alkyl; C 2-10 alkenyl; C 2-10 alkinyl; aryl; aryl-C 1-10 alkyl; C 3-10 heterocyclyl; C 5-10 heteroaryl; halo, CF 3 ; NO 2 ; NHC(O)R*, OR, said alkyl, alkenyl, alkinyl, aryl, heterocyclyl, or heteroaryl being optionally substituted; or R 5 and R 6 together form a 5- or 6-member aryl, heterocyclyl or heteroaryl group; R is hydrogen or C 1-6 alkyl; R* is hydrogen, or C 1-6 alkyl, or OH, wherein the optional substituents are preferably selected from the group of one to three OH, C 1-6 alkyl, halo, NO 2 , C 1-6 alkoxy, and CF3, or a pharmaceutically acceptable salt thereof.

  该发明涉及细胞增殖、血管生成、生育和肌肉收缩的抑制剂，其特征在于以下公式I1： 其中，X、Y和Z独立表示C或N；------是一个可选的双键；n为0或1；R1、R2和R4独立表示氢、化学键、C1-10烷基；C2-10烯基；C2-10炔基；芳基；芳基-C1-10烷基；C3-10杂环烷基；C5-10杂芳基；卤素、三氟甲基；NO2；NHC(O)R*、OR，所述的烷基、烯基、炔基、芳基、芳基烷基、杂环烷基或杂芳基可以是可选的取代基；R3、R5和R6独立表示氢、C1-10烷基；C2-10烯基；C2-10炔基；芳基；芳基-C1-10烷基；C3-10杂环烷基；C5-10杂芳基；卤素、三氟甲基；NO2；NHC(O)R*、OR，所述的烷基、烯基、炔基、芳基、芳基烷基、杂环烷基或杂芳基可以是可选的取代基；或者R5和R6一起形成一个5-或6-成员的芳基、杂环烷基或杂芳基；R为氢或C1-6烷基；R*为氢、或C1-6烷基、或OH，其中可选的取代基优选从一个到三个OH、C1-6烷基、卤素、NO2、C1-6烷氧基和三氟甲基中选择，或其药学上可接受的盐。
• Organic molecules for use in organic devices
  申请人：CYNORA GMBH

  公开号：US11276825B2

  公开（公告）日：2022-03-15

  An organic molecules for use in optoelectronic devices is disclosed having a structure of formula A1: where A, RN, Ra and R2 are as defined herein.

  公开了一种用于光电子器件的有机分子，其结构式为A1:其中A，RN，Ra和R2的定义如本文所述。
• Process for preparing pyrylium salts
  申请人：Eastman Kodak Company

  公开号：US04642359A1

  公开（公告）日：1987-02-10

  A process for selectively preparing isomers of polysubstituted pyrylium salts from isoolefins or isoolefin precursors comprises diacylating the isoolefin or isoolefin precursor with a carboxylic acid anhydride in the presence of an acid having a Hammett acidity function, at about 22.degree.-25.degree. C. when pure, between -10 and -5. This method is selective to obtain the most substituted isomer of pyrylium salt that can be obtained from the isoolefin or isoolefin precursor.

  从异构烯或异构烯前体中选择性制备多取代吡啶锭的过程包括在存在具有Hammett酸度功能的酸的情况下，使用羧酸酐对异构烯或异构烯前体进行二酰基化，在纯度为约22℃至25℃时，酸度函数在-10至-5之间。该方法是选择性的，可获得从异构烯或异构烯前体中获得的最多取代的吡啶锭异构体。
• INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：Gonzalez Javier

  公开号：US20070015764A1

  公开（公告）日：2007-01-18

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了公式(4)的化合物及其药学上可接受的盐和溶剂，这些化合物可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且还可用于治疗HCV感染的HCV感染哺乳动物。本发明还提供了包含公式(4)的化合物、其药学上可接受的盐和溶剂的制药组合物。此外，本发明还提供了中间体化合物和制备公式(4)的方法。
• Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same
  申请人：Gonzalez Javier

  公开号：US20090281122A1

  公开（公告）日：2009-11-12

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了式（4）的化合物及其药学上可接受的盐和溶剂化物，它们可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且也可用于治疗HCV感染的HCV感染的哺乳动物。本发明还提供了包含式（4）的化合物、它们的药学上可接受的盐和溶剂化物的制药组合物。此外，本发明还提供了用于制备式（4）的化合物的中间体和方法。